First patient receives Forzinity in Mighty Therapeutics’ Phase IV study

​

Mighty Therapeutics has dosed the first patient in 4TAZPower, its global Phase IV confirmatory study assessing Forzinity injection in those aged at least five years with Barth syndrome.

The post First patient receives Forzinity in Mighty Therapeutics’ Phase IV study appeared first on Hospital Management.

 

Back to the Featured Stories
First patient receives Forzinity in Mighty Therapeutics’ Phase IV study

Featured Stories

FDA clears Medtronic’s LigaSure RAS Maryland device
SpliSense begins Phase IIb SPL84 trial for cystic fibrosis
Viatris’ Wakix receives Japanese approval to treat OSAS and narcolepsy
Hyperfine concludes Contrast PMR study enrolment for Swoop MRI system
Arrowhead reports top-line results in mixed hyperlipidaemia trial

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us